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In vitro effect of bergamot (Citrus bergamia)
juice against cagA-positive and-negative
clinical isolates of Helicobacter pylori
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Abstract
Background: Helicobacter pylori infection has been associated with chronic gastritis, peptic ulcer and gastric carcinoma
as over half of the world's population is colonized with this gram-negative bacterium. Due to the increasing
antibiotic resistance, its eradication rates fails in a great portion of patients. A number of studies showed that
molecules largely distributed in commonly consumed fruits and vegetables may have antimicrobial activity. The aim of
the present study was to investigate the effect of bergamot juice (BJ) against Helicobacter pylori in vitro. The potential
therapeutic combination between BJ and the antibiotics amoxicillin (AMX), clarithromycin (CLA) and metronidazole
(MTZ) has also been evaluated.
Methods: The minimum inhibitory concentration (MIC) of BJ, AMX, CLA and MTZ against 2 ATCC and 32 clinical
isolates of H. pylori was assayed according to CLSI. The checkerboard method was used to determine the efficacy
of the association BJ with the three reference antibiotics.
Killing curves were performed on the two cagA-positive ATCC strains of H. pylori (ATCC 43504 and ATCC 49503), on the
clinical isolate cagA-positive HP6 strain of H. pylori and on the clinical isolate cagA-negative HP61 strain of H. pylori.
Results: BJ (2.5 %, v/v) inhibited the growth of 50 % of the H. pylori clinical isolates, whereas 5 % (v/v) inhibited 90 %.
AMX was the most effective antibiotic against the reference strains and the clinical isolates, followed by CLA and MTZ.
In the combination assays, synergism was observed between BJ and AMX and between BJ and MTZ against both the
reference strains and the clinical isolates. Indifference was observed between BJ and CLA.
Conclusions: BJ was effective in vitro against H. pylori and the genotype status of the clinical strains may have an
impact on its susceptibility. The synergistic combination of BJ and antibiotics could be used to prevent or treat
resistance.
Keywords: Bergamot, H. pylori, Antimicrobial, Citrus bergamia, Natural products, Antibiotic resistance, Synergism,
Complementary and alternative medicines
Background
Infection with Helicobacter pylori (H. pylori), identified as
group 1 carcinogen by the International Agency for Re-
search on Cancer, has been associated with chronic gastri-
tis, peptic ulcer and gastric carcinoma [1, 2]. Its incidence
is highly variable in relation to geography, ethnicity, age
and socioeconomic factors. Infection rates are similar for
men and women and increase progressively with age. The
estimated prevalence is 70 % in developing countries,
mainly in the young population, and 30 %–40 % in the
developed countries [3].
The virulence of the infecting strain is believed to affect
the severity of gastroduodenal diseases caused by H. pyl-
ori. Despite the wide genetic diversity of H. pylori involved
in its pathogenesis, a number of genetic loci, such as the
cytotoxin-associated gene (cagA) and the vacuolating cyto-
toxin gene (vacA), have been identified. VacA, present in
all H. pylori strains, contains two variable parts relevant to
virulence [4], whereas cagA, not present in every H. pylori
strain, is a marker for a pathogenicity island (PAI) [5]
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associated with more severe clinical outcomes and an in-
creased risk of developing gastric cancer and peptic ulcer
[6]. Although heterogeneity in single cagA and vacA genes
in H. pylori have been associated to specific clinical effects
[7], some studies suggested that genetic heterogeneity is
due to geographical diversity and host environment [8].
The standard treatment for H. pylori related disease is
a combination of antimicrobial agents and anti-acid
agents [9]. The first line of treatment regimens consist
of a triple therapy, carried out through the recruitment
of a proton pump inhibitor (PPI) and two antibiotics,
amoxicillin (AMX) and clarithromycin (CLA), or metro-
nidazole (MTZ) and CLA. Quadruple therapy obtained
by the association of PPI, bismuth and two antibiotics
(AMX +CLA, or MTZ + tetracycline (TET)) is equiva-
lent or little superior in the eradication rates, although
reducing the compliance [3]. However, standard PPI-
based therapy fails in up to 30 % of patients, and eradi-
cation rates were reduced to 70–80 % over the last few
years. This is mostly due to increasing antibiotic resist-
ance which favors recurrence of H. pylori infection, par-
ticularly high in developing countries.
Due to common side effects and the development of
antimicrobial resistance [10], a number of natural com-
pounds have been tested as alternatives [11–13]. We
have recently demonstrated that polyphenolic fractions
from almond skin were active against standard strains
and clinical isolates of H. pylori [14].
Citrus bergamia Risso et Poiteau (bergamot) is an en-
demic plant of the Calabrian region in Southern Italy,
mostly used for the extraction of its essential oil from
the fruit peel, much employed in the fragrance industry
and lesser exploited in pharmaceutical and food applica-
tions. Bergamot juice (BJ), obtained from the endocarp
of the fruit, is considered a byproduct barely utilized by
the food industry [15]. Recently, we focused on potential
beneficial effects of BJ. We demonstrated that BJ inhib-
ited signaling pathways linked to cancer-associated ag-
gressive phenotype, thus reducing proliferation, adhesion
and migration both in vitro [16] and in vivo [17]. In
addition, we documented that the antiproliferative effect
of BJ was due to its flavonoid fraction (BJe), which inhib-
ited proliferation inducing apoptosis in human colon
cancer cells [18]. Moreover, we provided evidence that
BJe possess antioxidant effects [19] and inhibited both
gene expression and secretion of LPS-induced pro-
inflammatory cytokines in a model of LPS-stimulated
THP-1 cell line [20]. Moreover, BJe exerted anti-
inflammatory effects also in an animal model of experi-
mental colitis [21], suggesting a possible role in treating
rheumatoid arthritis with a good balance between effi-
cacy and safety [22]. Earlier studies demonstrated that
the polyphenolic fraction of BJ reduced serum choles-
terol, triglycerides and glycaemia in patients suffering
from metabolic syndrome [23], supporting previous find-
ings obtained in animal models [24].
The aim of the present study was to investigate the
antimicrobial properties of BJ against H. pylori strains




BJ was obtained by hand-squeezing fruits of Citrus berga-
mia Risso et Poiteau collected in the Calabrian region
(Southern Italy). Prof. Antonio Rapisarda (pharmaceutical
botany expert, University of Messina) has provided the
identification of Citrus bergamia fruits used to obtain the
bergamot juice employed in this experimental study. A
voucher specimen of the plant, identified according to
the botanical literature, was deposited in the herbarium
(H.N. 3263–3266 # CBSD) of the Dipartimento di
Scienze del Farmaco e Prodotti per la Salute of University
of Messina (Italy).
Aliquots of BJ were stored at −20 °C until further
use. The flavonoid composition of BJ was evaluated by
RP-HPLC as previously reported [16]. The major flavo-
noids identified in BJ were eriocitrin, neoeriocitrin,
naringin and neohesperidin, of which the most abun-
dant compound was neoeriocitrin (29 % of total),
followed by neohesperidin (27 % of total). No significant
differences in amounts of eriocitrin and naringin were
detected. Minor identified compounds included a num-
ber of glucosides, such as apigenin-6,8-di-C-glucoside,
diosmetin-6,8-di-C-glucoside and crisoeriol-7-O-neohe-
speridoside-49-glucoside.
Patients, H. pylori strains and culture conditions
Two reference American Type Culture Collection strains of
Helicobacter pylori (ATCC 43504 and ATCC 49503) and
thirty two clinical isolates recovered from gastric biopsy
samples of dyspeptic adults (23 women, 9 men; average
age, 51 years) undergoing digestive endoscopy at the
Endoscopy Unit of the Department of Internal Medicine of
the University of Messina, Messina, Italy, were used in this
study [14]. None of the patients had previously undergone
eradication therapy. All study subjects gave their informed
consent and the study was approved by the local ethical
committee (Comitato Etico Scientifico A.O.U. Policlinico
"G. Martino", Messina, Italy). Diagnosis of peptic ulcer and
non-ulcer dyspepsia (NUD) or gastritis was based on endo-
scopic examination of the stomach and duodenum. Biopsy
samples were taken for each patient for culture. Isolates
were derived from patients suffering from gastritis (n = 27;
84.37 %), or NUD (n = 5; 15.62 %).
Gastric biopsy specimens were placed in the sterile
screw-capped tubes containing 0.5 ml sterile saline and
transported to the microbiology laboratory within 2 h.
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Samples were soaked and sowed in selective (Pylori agar,
BioMérieux, Florence, Italy) and non-selective (Columbia
agar with 7 % horse blood, CB, Oxoid, Milan, Italy) culture
media. Cultures were incubated for 7 days at 37 °C under
microaerophilic conditions. Grown bacteria were identified
as H. pylori by typical morphology, Gram staining results
and positive reactions to oxidase, catalase, and urease activ-
ities. The molecular identification of the tested strains has
been previously reported [14].
All strains were harvested by suspension in Brucella
broth (Becton Dickinson Italia, Milan, Italy) supplemented
with 10 % fetal bovine serum (BB, Euroclone, Milan, Italy)
and 30 % glycerol and stored in liquid nitrogen until used.
Susceptibility studies
The minimum inhibitory concentration (MIC) of BJ,
amoxicillin (AMX, Sigma, Milan, Italy), clarithromycin
(CLA, Sigma, Milan, Italy) and metronidazole (MTZ,
Sigma, Milan,Italy) was assayed by the standard agar
dilution method according to the guidelines of the
National Committee for Clinical Laboratory Standards
[25] using CB. Frozen stock cultures were thawed and
subcultured on CB and grown for 3 days under micro-
aerophilic conditions. Bacterial growth was taken from the
plates, resuspended in BB and grown under shaking
(125 rpm) at 37 °C for 24 h. H. pylori cultures in the expo-
nential phase of growth were diluted with BB to contain
about 5 × 107 CFU/ml by adjusting the turbidity of the
suspension to match the MacFarland no. 1 standard. Ten-
microliter aliquots of the suspensions were inoculated on
CB containing twofold serial dilutions of the compound
tested, ranging from 80 (%, v/v) to 0.156 (%, v/v).
Compound-free CB media were included in each experi-
ment to confirm the viability of the inoculum and to ob-
serve the growth of any contaminants. All plates were
incubated at 37 °C in a microaerophilic atmosphere
and examined after 3 days. The MIC was considered
the lowest concentration at which the compound inhib-
ited the development of visible bacterial growth on the
agar plates.
Combination assays
In the combination assays, the “checkerboard” procedure
described by White et al. [26] was followed to determine
the efficacy of the association BJ with the three reference
antibiotics against all tested strains. The test compounds
represented by each antibiotic (AMX, CLA or MTZ)
was serially diluted on the x axis, ranging from 1 to 1/64
x MIC, with increasing concentrations of BJ ranging
from 1/32 to 1 x MIC on the y axis.
MIC data were converted into fractional inhibitory
concentration (FIC), defined as ratio of the concentra-
tion of the antimicrobial at an inhibitory concentration
with a second compound to the concentration of the
antimicrobial by itself as previously reported [27].
FICA =MIC of A with B/MIC of A
The FIC index was then calculated as follows: FIC
index = FICA + FICB.
All MIC determinations were performed in duplicate
for each strain.
Time-kill curves
Killing curves were performed on the two cagA-positive
ATCC strains of H. pylori (ATCC 43504 and ATCC
49503), on the clinical isolate cagA-positive HP6 strain
of H. pylori and on the clinical isolate cagA-negative
HP61 strain of H. pylori. Tubes containing BJ at concen-
trations corresponding to 0.5, 1, 2, 4 and 8 x MIC were
inoculated with a suspension of each test strain, yielding
to a final bacterial density of 5 × 106 cfu/ml and then in-
cubated at 37 °C under microaerophilic conditions
(GENbag microaer for microaerophilic bacteria, BioMer-
ieux). A growth control was also performed. Samples for
viable counting were withdrawn at 0, 2, 4, 6, 8, and 24 h.
At least four dilutions of each sample were spread in
triplicate on Columbia agar plates containing horse
blood (7 %, Oxoid), incubated at 37 °C under microaer-
ohpilic conditions and counted after 3 days.
Time-kill studies were also performed using a combin-
ation of each antibiotic and BJ: solutions of the two
drugs were added to tubes containing a suspension of
single test strains giving a final bacterial concentration
of 5 × 106 cfu/ml. The final concentrations of drugs in
each tube were the following: (1) control (without drug);
(2) BJ (1 x MIC); (3) AMX (1 x MIC); (4) CLA (1 x
MIC); (5) MTZ (1 x MIC); (6) BJ (1 x MIC) and AMX
(1 x MIC); (7) BJ (1 x MIC) and CLA (1 x MIC); (8) BJ
(1 x MIC) and MTZ (1 x MIC). All experiments were
performed in triplicate for each strain.
Results
Minimum inhibitory concentrations
The MICs of BJ, AMX, CLA and MTZ against the three
reference strains and the clinical isolates of H. pylori are
Table 1 MICs of bergamot juice (% v/v) and reference
antibiotics (amoxicillin, clarithromycin and metronidazole
expressed as μg/ml) against ATCC strains and 32 clinical isolates
of H. pylori
ATCC CI
Compound 43504 49503 MIC50 MIC90 MIC range
BJ 2.5 5.0 2.5 5.0 0.625-5.0
AMX 0.0312 0.0156 0.0312 0.0625 0.0156-0.125
CLA 0.0625 0.0312 0.0625 0.125 0.0312-0.125
MTZ 64.0 8.0 2.0 4.0 1.0-16.0
MICs minimal inhibitory concentrations, BJ bergamot juice, AMX amoxicillin,
CLA clarithromycin, MTZ metronidazole, CI clinical isolates of H. pylori
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reported in Table 1. Results of negative controls indi-
cated the complete absence of inhibition of all the H.
pylori strains tested (data not shown). BJ (2.5 %) inhib-
ited the growth of 50 % of the clinical isolates tested,
whereas 5 % (v/v) inhibited 90 %. AMX was the most ef-
fective antibiotic against the reference strains and the
clinical isolates, followed by CLA and MTZ. In the com-
bination assays, the lowest FIC index calculated against
the reference strains of H. pylori was 0.187, which was
obtained by the combination of BJ with MTZ (Table 2).
The same combination produced the lowest FICI 50
and FICI 90 against the 32 clinical isolates of H. pylori
(Table 2). Although the interpretation of the FIC indices
depends on which of the several definitions described
in the literature are used, in this study we have
considered as synergistic if the FIC index is </=0.5,
additive or indifferent if > 0.5 but </= 4 and antagonis-
tic if > 4. Synergism was observed between BJ and
AMX and between BJ and MTZ against both the refer-
ence strains and the clinical isolates of H. pylori. Indif-
ference was observed between BJ and CLA for all the
combinations tested.
Time-kill curves
Concentration dependent killing was observed with BJ
against all the strains tested (Fig. 1 a, b, c and d). At 2 h
there was a > 3log10 difference in CFU between BJ
(1.25 %) and BJ (20.0 %) with H. pylori ATCC 49503
(Fig. 1b) and complete bacterial killing was achieved
within 8 h exposure at BJ (20 % and 10 %) and within
24 h exposure at BJ (5 %). BJ gave overall less killing
against H. pylori ATCC 43504, although a complete bac-
terial killing was achieved within 6 h exposure at BJ
(20 %, Fig. 1a). This trend could be explained by the in-
creased resistance to reference antibiotics of H. pylori
ATCC 43504 compared to H. pylori ATCC 49503
(Table 1). The killing curves of BJ against the clinical
isolate HP6 (cagA-positive) and the clinical isolate HP61
(cagA-negative) have shown HP61 was overall more sen-
sitive than HP6 (Fig. 1c and d): a very rapid bactericidal
effect was obtained with BJ (20 %) against HP61 after
Table 2 FIC index of the association bergamot juice with
reference antibiotics (amoxicillin, clarithromycin and metronidazole)
against ATCC strains and 32 clinical isolates of H. pylori
ATCC CI
Association 43504 49503 FICI 50 FICI 90 FICI range
BJ/AMX 0.375 0.375 0.187 0.308 0.093-0.49
BJ/ CLA 1 0.75 0.75 1.06 0.56-1.24
BJ/ MTZ 0.501 0.187 0.093 0.192 0.093-0.75
BJ bergamot juice, AMX amoxicillin, CLA clarithromycin, MTZ metronidazole, CI
clinical isolates of H. pylori
Fig. 1 a. Killing curves for bergamot juice (BJ) against H. pylori ATCC 43504. ▲, 1.25 %; ■, 2.50 %; □, 5.0 %; ▲, 10.0 %; ●, 20.0 %; ♦, control. b.
Killing curves for bergamot juice (BJ) against H. pylori ATCC 49503.▲, 1.25 %; ■, 2.50 %; □, 5.0 %;▲, 10.0 %; ●, 20.0 %; ♦, control. c. Killing curves for
bergamot juice (BJ) against H. pylori HP6 (cagA-positive). ▲, 1.25 %; ■, 2.50 %; □, 5.0 %; ▲, 10.0 %; ●, 20.0 %; ♦, control. d. Killing curves for
bergamot juice (BJ) against H. pylori HP61 (cagA-negative). ▲, 1.25 %; ■, 2.50 %; □, 5.0 %; ▲, 10.0 %; ●, 20.0 %; ♦, control
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2 h exposure, whereas complete bacterial killing was
achieved with BJ (20 %) against HP6 after 6 h exposure.
These results suggest the genotype status of the clinical
strains of H. pylori may have an impact on their suscep-
tibility to natural antimicrobial compounds.
In the combination assays, the association of BJ (1 x
MIC) with the reference antibiotics (AMX, 1 x MIC,
CLA, 1 x MIC, and MTZ, 1 x MIC) determined a reduc-
tion of > 6log10 for H. pylori ATCC 49503 after 8 h in-
cubation time (Fig. 2b) and for H. pylori ATCC 43504
after 24 h incubation time (Fig. 2a). Similarly to the kill-
ing trends obtained with BJ alone, the association of BJ
with the three reference antibiotics was more effective
against H. pylori ATCC 49503 than H. pylori ATCC
43504. In the association killing curve a synergistic effect
was also observed when treating the clinical isolate HP6
(Fig. 2c) and the clinical isolate HP61 (Fig. 2d). The most
effective combination was BJ (1 x MIC) and CLA (1 x
MIC) against both clinical isolates, with more rapid bac-
terial killing achieved with the cagA-positive strain (HP6).
This data confirmed the combination between BJ and the
three reference antibiotics had a synergistic effect against
H. pylori (both ATCC and clinical isolates). The effect of
the association was irrespective of the genotype status of
the tested strains.
Discussion
The results reported in the present study demonstrated for
the first time that BJ was effective against H. pylori strains,
both alone or in combination with antibiotics. We have
recently shown that almond skins were active against the
same strains with different virulence irrespective of the
cagA and vacA status [14]. In the present study, the geno-
type status of the clinical isolates affected the suppression
of growth exerted by BJ, the cagA-negative strain being
more sensitive than the cagA-positive. The three reference
antibiotics (AMX, MTZ and CLA) generally used for the
treatment of H. pylori were effective in combination with
BJ: the standardization of combination therapies may be
useful against the increasing numbers of multiple drug
resistant strains. All H. pylori tested in this study were sus-
ceptible to amoxicillin (MIC90 0.25 μg/ml), two (6 %) out of
32 clinical isolates tested were clarithromycin resistant, one
of which isolated from a patient suffering from gastritis har-
bouring the cagA+/vacAs1/m1 genotype, four (12 %) out of
32 clinical isolates tested were resistant to metronidazole.
Fig. 2 a. Killing curves for bergamot juice (BJ) with reference antibiotics (amoxicillin, AMX, metronidazole, MTZ, clarithromycin, CLA) against H.
pylori ATCC 43504. ♦, BJ (1 x MIC); ■, AMX (1 x MIC); ▲, MTZ (1 x MIC); ●, CLA (1 x MIC); □, BJ (1 x MIC) with AMX (1 x MIC);▲, BJ (1 x MIC) with
MTZ (1 x MIC);○, BJ (1 x MIC) with CLA (1 x MIC);×, control. b. Killing curves for bergamot juice (BJ) with reference antibiotics (amoxicillin, AMX,
metronidazole, MTZ, clarithromycin, CLA) against H. pylori ATCC 49503. ♦, BJ (1 x MIC); ■, AMX (1 x MIC); ▲, MTZ (1 x MIC); ●, CLA (1 x MIC); □, BJ
(1 x MIC) with AMX (1 x MIC);▲, BJ (1 x MIC) with MTZ (1 x MIC); ○, BJ (1 x MIC) with CLA (1 x MIC); ×, control. c. Killing curves for bergamot juice (BJ)
with reference antibiotics (amoxicillin, AMX, metronidazole, MTZ, clarithromycin, CLA) against H. pylori HP6 (cagA-positive). ♦, BJ (1 x MIC); ■, AMX
(1 x MIC); ▲, MTZ (1 x MIC); ●, CLA (1 x MIC); □, BJ (1 x MIC) with AMX (1 x MIC); ▲, BJ (1 x MIC) with MTZ (1 x MIC); ○, BJ (1 x MIC) with CLA
(1 x MIC); ×, control. d. Killing curves for bergamot juice (BJ) with reference antibiotics (amoxicillin, AMX, metronidazole, MTZ, clarithromycin,
CLA) against H. pylori HP61 (cagA-negative). ♦, BJ (1 x MIC); ■, AMX (1 x MIC); ▲, MTZ (1 x MIC); ●, CLA (1 x MIC); □, BJ (1 x MIC) with AMX
(1 x MIC); ▲, BJ (1 x MIC) with MTZ (1 x MIC); ○, BJ (1 x MIC) with CLA (1 x MIC); ×, control
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We have shown that the interactions between BJ and
the reference antibiotics (CLA, MTZ and AMX) can im-
prove the effectiveness of the synthetic antibiotic against
H. pylori. Although the exact mechanism of action is not
known, we believe that the synergistic effect may be due
to the initial damage of the microbial lipid membrane by
the plant compound, which would increase the permeabil-
ity of the bacteria to the antibiotic. Trombetta et al. [28]
have demonstrated that the damage of the microbial lipid
membrane function by essential oils could be related to
the lipid composition and the net surface charge of the
membrane, the Gram-negative bacteria presenting a
strong negative charge conferred by the lipopolysac-
charide. Other reports on the mechanisms of action of
isoflavones and chalcones have indicated an inhibition
of the urease secreted by H. pylori which is crucial for
its survival under the acidic conditions of the human
stomach [29, 30]. Several flavone derivatives and other
polyphenols in plants are able to inhibit ion and urea
conduction and cell vacuolation by VacA, major virulence
factor of H. pylori [31]. The anti-adhesive properties of
BJ could also be responsible for its activity against H.
pylori [16, 17].
The indifferent effect observed by the combination of BJ
with CLA against H.pylori could be due to a number of
mechanisms, such as inhibition of antibiotic uptake by the
bacterial cells compared to MTZ and AMX. Alternatively,
direct interaction between the two compounds may result
in the reduction of the inhibitory effect. However, in the
time-kill studies, the most effective combination was BJ
and CLA against both clinical isolates and a synergistic
interaction was detected against the two ATCC strains
tested.
We have previously demonstrated that polyphenols
present in bergamot peel were found to be active against a
range of Gram-negative bacteria including Escherichia
coli, Pseudomonas putida and Salmonella enterica, and
their antimicrobial potency increased after enzymatic
deglycosylation [32]. The most representative polyphenols
present in bergamot peel were neohesperidin and hespere-
tin (aglycone), neoeriocitrin and eriodictyol (aglycone),
naringin and naringenin (aglycone). We believe that the
same compounds present in BJ could be responsible for
the antimicrobial effect against H. pylori strains [3–7].
Conclusion
The results of the present study demonstrated that BJ
was effective against H. pylori strains in vitro, both alone
and in combination with antibiotics, and could therefore
be used as novel strategy for the treatment of antibiotic
resistance. Further studies on the mechanism of action
of bergamot juice and its interaction with synthetic antibi-
otics are warranted.
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